Skip to main content
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. — Investor Relations & Filings

Ticker · CCCC ISIN · US12529R1077 US Manufacturing
Open in API
Filings indexed 497 across all filing types
Latest filing 2020-10-06 Director's Dealing
Country US United States of America
Listing US CCCC

About C4 Therapeutics, Inc.

https://c4therapeutics.com/

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of a new class of small-molecule medicines through targeted protein degradation (TPD). The company's proprietary TORPEDO (Target Oriented Protein Degrader Optimizer) platform is utilized to create therapeutics that selectively destroy disease-causing proteins. C4 Therapeutics' primary focus is on developing treatments for cancer and other diseases. Its clinical pipeline includes investigational candidates such as cemsidomide (CFT7455) for hematologic malignancies, CFT8919 for solid tumors with specific genetic mutations, and CFT1946 for BRAF V600 mutant cancers.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-10-06 English
FORM 4 SUBMISSION
Director's Dealing
2020-10-06 English
FORM 4 SUBMISSION
Director's Dealing
2020-10-06 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans and employee stock purchase plans. It includes detailed information about the plans, the number of shares to be registered, and legal provisions related to indemnification of directors and officers. This type of filing is a registration statement related to capital raising through employee stock plans, not a financial report, earnings release, or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains substantive information about the registration of shares under stock plans, confirming it is not merely an announcement or a certification.
2020-10-02 English
424B4
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for an initial public offering (IPO) of common stock by C4 Therapeutics, Inc. It includes extensive information typical of a registration statement or prospectus filed under SEC rules, such as risk factors, use of proceeds, dividend policy, capitalization, dilution, selected consolidated financial data, management's discussion and analysis, business overview, management, executive compensation, principal stockholders, description of capital stock, underwriting, legal matters, and consolidated financial statements. The filing is identified as a '424B4' prospectus, which is a type of prospectus filed pursuant to SEC Rule 424(b)(4) related to securities offerings. This document is not an annual report, earnings release, management discussion, or any other report type but rather a capital markets offering document. According to the provided filing categories, the closest and most appropriate classification for this document is 'Capital/Financing Update (CAP)', which covers updates on company fundraising and financing activities such as IPOs and stock offerings. The document length and content confirm it is a full prospectus, not a brief announcement or a regulatory filing notice. Therefore, the classification is CAP with high confidence.
2020-10-02 English
Regulatory Filings 2020
Regulatory Filings
2020-10-02 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.